Your browser doesn't support javascript.
loading
Associations of different types of statins with the risk of open-angle glaucoma: a systematic review and network meta-analysis.
Pan, Ssu-Yu; Chen, Yun-Yu; Hsu, Min-Yen; Sheen, Yi-Jing; Weng, Chien-Hsiang; Lu, Yi-An; Wang, I-Jong; Wu, Mei-Hua; Chou, Chien-Chih.
  • Pan SY; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Chen YY; Department of Ophthalmology, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Hsu MY; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Sheen YJ; Heart Rhythm Center, Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Weng CH; Department of Post-Baccalaureate, National Chung Hsing University, Taichung, Taiwan.
  • Lu YA; College of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
  • Wang IJ; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Wu MH; Department of Ophthalmology, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Chou CC; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Article en En | MEDLINE | ID: mdl-39212799
ABSTRACT

PURPOSE:

Previous studies implied that different types of statins may pose divergent impacts on the risk of glaucoma onset. This study aimed to comprehensively evaluate the effects of various statins on the risk of glaucoma occurrence.

METHODS:

PubMed, Cochrane CENTRAL, Embase, and Web of Science were searched from February 1994 to February 2024. We included studies that investigated the effects of various types of statins, fibrates, ezetimibe, cholestyramine, niacin, PCSK9 inhibitors, omega-3 fatty acids, and any cholesterol-lowering medications on glaucoma onset or progression. The revised Cochrane risk-of-bias tool for randomized trials (RoB 2.0) and the Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-1) tool were used to assess the quality of randomized controlled trials (RCTs) and non-RCTs, respectively. The frequentist network meta-analysis framework was utilized to evaluate the comparative effectiveness, with the random effects model applied.

RESULTS:

This network meta-analysis comprised 12 studies, encompassing 262,217 individuals and including cholesterol-lowering medications such as statins, fibrates, ezetimibe, cholestyramine, niacin, and omega-3 fatty acids. Our findings demonstrate that comparing to the placebo, rosuvastatin (risk ratio [RR], 1.23; 95% confidence interval [CI], 1.03 to 1.46), simvastatin (RR, 1.21; 95% CI, 1.02 to 1.43), and pravastatin (RR, 1.20; 95% CI, 1.01 to 1.43) increased the risk of glaucoma onset with statistical significance.

CONCLUSION:

Rosuvastatin, simvastatin, and pravastatin were each associated with a significantly increased risk of glaucoma onset. We advise medical practitioners to exercise caution when prescribing these specific statins for patients who are at risk of developing glaucoma. KEY MESSAGES What is known Previous studies have suggested a link between statins and the risk of developing glaucoma. However, there is still ongoing debate regarding the specific effects of each type of statin on the onset of glaucoma. What is new This network meta-analysis comprehensively evaluated the effects of various statins on the risk of glaucoma onset. Rosuvastatin, simvastatin, and pravastatin were associated with a significantly increased risk of glaucoma onset.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article